Allergan Sues Four Generics Makers for Infringement of Linzess Generics

Allergan, along with Ironwood Pharmaceuticals, has filed a suit against five generics companies, alleging infringement of nine patents covering its irritable bowel syndrome drug, Linzess.

The companies are asking the court for an injunction to block Teva, Mylan, Sandoz, and Aurobindo from marketing Linzess generics until the applicable patents expire in 2031. If the companies launch generics before the patents become invalid, Allergan is requesting monetary relief.

The complaint, filed in U.S. District Court for the District of Delaware, contends the companies submitted their ANDAs on the grounds that the patents are either invalid, unenforceable, or would not be infringed on by a generic.